Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study
| العنوان: | Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGroup-Symptom Benefit Study |
|---|---|
| المؤلفون: | Yeh Chen Lee, Madeleine T King, Rachel L O'Connell, Anne Lanceley, Florence Joly, Felix Hilpert, Alison Davis, Felicia T Roncolato, Aikou Okamoto, Jane Bryce, Paul Donnellan, Amit M Oza, Elisabeth Avall-Lundqvist, Jonathan S Berek, Jonathan A Ledermann, Dominique Berton, Jalid Sehouli, Amanda Feeney, Marie-Christine Kaminsky, Katrina Diamante, Martin R Stockler, Michael L Friedlander |
| المصدر: | International Journal of Gynecologic Cancer. 32:761-768 |
| بيانات النشر: | BMJ, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Ovarian Neoplasms, Oncology, Obstetrics, Gynecology and Reproductive Medicine, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Humans, Obstetrics and Gynecology, Reproduktionsmedicin och gynekologi, Female, Carcinoma, Ovarian Epithelial, ovarian cancer, quality of life (PRO), palliative care, medical oncology |
| الوصف: | Objective The Gynecologic Cancer InterGroup (GCIG)-Symptom Benefit Study was designed to evaluate the effects of chemotherapy on symptoms and health-related quality of life (HRQL) in women having chemotherapy for platinum resistant/refractory recurrent ovarian cancer (PRR-ROC) and potentially platinum sensitive with >= 3 lines of chemotherapy (PPS-ROC >= 3). Methods Participants completed the Measure of Ovarian Cancer Symptoms and Treatment (MOST) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire QLQ-C30 questionnaires at baseline and every 3-4 weeks until progression. Participants were classified symptomatic if they rated >= 4 of 10 in at least one-third of symptoms in the MOST index. Improvement in MOST was defined as two consecutive scores of = 10 points above baseline in the QLQ-C30 summary score scale (range 0-100). Results Of 948 participants enrolled, 910 (96%) completed baseline questionnaires: 546 with PRR-ROC and 364 with PPS-ROC >= 3. The proportions of participants symptomatic at baseline as per MOST indexes were: abdominal 54%, psychological 53%, and disease- or treatment-related 35%. Improvement was reported in MOST indexes: abdominal 40%, psychological 35%, and disease- or treatment-related 38%. Median time to improvement in abdominal symptoms occurred earlier for PRR-ROC than for PPS-ROC >= 3 (4 vs 6 weeks, p=0.044); median duration of improvement was also similar (9.0 vs 11.7 weeks, p=0.65). Progression-free survival was longer among those with improvement in abdominal symptoms than in those without (median 7.2 vs 2.5 months, p= 3 (p=0.29), and 102/481 (21%) of those with abdominal symptoms at baseline. Conclusion Over 50% of participants reported abdominal and psychological symptoms at baseline. Of those, 40% reported an improvement within 2 months of starting chemotherapy. Approximately one in six participants reported an improvement in HRQL. Symptom monitoring and supportive care is important as chemotherapy palliated less than half of symptomatic participants. Funding Agencies|NHMRCNational Health and Medical Research Council of Australia [1063012, 570893]; Target Ovarian Cancer [UCL-P001AL]; Cancer Research UKCancer Research UK; UCL Cancer Trials Centre [C444/A15953]; Australian Government through Cancer AustraliaAustralian Government; NHMRC Program grantNational Health and Medical Research Council of Australia; Department of HealthEuropean Commission |
| وصف الملف: | application/pdf |
| تدمد: | 1525-1438 1048-891X |
| DOI: | 10.1136/ijgc-2021-003142 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c5ad9e5dd812ecc7b42ea5fd8c6dfad1 https://doi.org/10.1136/ijgc-2021-003142 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c5ad9e5dd812ecc7b42ea5fd8c6dfad1 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15251438 1048891X |
|---|---|
| DOI: | 10.1136/ijgc-2021-003142 |